Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2026 07:45 ET | Source: SNS Insider pvt ltd

Predictive Biomarkers Market to Reach USD 156.85 Billion by 2035; Rising Adoption of Precision Medicine and Targeted Therapies Driving Market Growth – SNS Insider

Austin, United States, March 17, 2026 (GLOBE NEWSWIRE) -- Predictive Biomarkers Market Size & Growth Analysis: According to SNS Insider, The Predictive Biomarkers Market size is estimated at...
February 04, 2022 08:00 ET | Source: Curesponse

Rafael and Curesponse to Collaborate on Precision Oncology Platform

HAIFA, Israel, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Curesponse (www.curesponse.com) and Rafael (https://www.rafael.co.il/) to collaborate on integrating Artificial Intelligence capabilities in...
June 04, 2021 09:00 ET | Source: Cellworks Group, Inc.

Cellworks Singula™ Delivers Superior OS and DFS Predictions for Brain Cancer Patients in myCare-022-03 Clinical Trial

SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...
June 04, 2021 09:00 ET | Source: Cellworks Group, Inc.

Cellworks Singula™ Accurately Predicts Clinical Outcome from Treatments in Patients with NSCLC

SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...
December 07, 2020 11:00 ET | Source: Cellworks Group, Inc.

Cellworks CBM Identifies Genomic Signatures Impacting HOXA Regulation that Determine Response for AML Patients with Monosomy 7

myCare-021-04 study finds genetic signatures associated with 100% remission rate fromAML induction therapy despite presence of Monosomy 7 SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE)...
December 07, 2020 11:00 ET | Source: Cellworks Group, Inc.

Cellworks Personalized Biosimulation Clinical Trials Achieve 90% Therapy Response Prediction Accuracy for AML and MDS Patients

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...
December 07, 2020 11:00 ET | Source: Cellworks Group, Inc.

Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...
December 07, 2020 11:00 ET | Source: Cellworks Group, Inc.

Cellworks CBM Biosimulation Identifies Genomic Causes for Induction Failure in AML Patients and Suggests Alternative Therapies

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...
May 29, 2020 08:00 ET | Source: Cellworks Group, Inc.

myCare Clinical Studies Show Cellworks Singula™ Achieves Superior Therapy Response Predictions for Brain Cancer Patients

SOUTH SAN FRANCISCO, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...
May 14, 2020 08:00 ET | Source: Cellworks Group, Inc.

Cellworks Singula™ Predicts Personalized Therapy Responses for AML and MDS Patients with Higher Accuracy than Physician Prescribed Treatments

SOUTH SAN FRANCISCO, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...